BioCentury | Jun 22, 2018
Finance

Regenerating eastward

...donors. Promethera has four hepatic programs -- two cell therapies developed in-house, another acquired from Cytonet GmbH & Co. KG...
...therapies. The mAb has anti-inflammatory effects in preclinical models. Promethera’s most advanced program, Heparesc from Cytonet...
...to change the company’s calculus. Although Promethera gained a facility in North Carolina through the Cytonet...
BioCentury | May 2, 2016
Company News

Cytonet, Promethera deal

...Promethera acquired Cytonet’s “key” assets, including Heparesc . Promethera also will receive a U.S. Cytonet facility...
...product manufacturing and liver sourcing with a U.S. organ procurement organization. A team of seven Cytonet...
...and that Cytonet’s lead shareholder will receive up to a 13% equity stake in Promethera. Cytonet GmbH & Co. KG...
BioCentury | Oct 26, 2015
Emerging Company Profile

Building bacteria

...data comparing Syn1010 with Ravicti. Gutiérrez-Ramos said cell therapies in the clinic require diet restrictions. Cytonet GmbH & Co. KG's...
...receiving HepaStem will be able to eat more proteins, but it still recommends low-protein diets. Cytonet...
...and Institutions Mentioned BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Boston University , Boston, Mass. Cytonet GmbH & Co. KG...
BioCentury | May 25, 2015
Finance

Innovation underfed

...up front plus $140 million in milestones. Another innovator in registration from the cohort is Cytonet GmbH & Co. KG...
...treat pediatric urea cycle disorders (UCD). Promethera Biosciences S.A. is a couple of years behind Cytonet...
...Germany Cardiorentis AG, Zug, Switzerland Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K. CureVac GmbH, Tuebingen, Germany Cytonet GmbH & Co. KG...
BioCentury | Feb 10, 2014
Clinical News

Liver cell therapy regulatory update

...U.S. and Canadian Phase II SELICA III trial in infants and children ages <=5 years. Cytonet GmbH & Co. KG...
BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...90% Novel drug class; deal with Sanofi- Pasteur, the vaccines division of Sanofi (Euronext:SAN; NYSE:SNY) Cytonet GmbH & Co. KG...
BioCentury | Apr 25, 2011
Clinical News

Human heterologous liver cells: Phase II started

...trial to evaluate infusions of human heterologous liver cells in 20 infant and pediatric patients. Cytonet GmbH & Co. KG...
BioCentury | Oct 25, 2010
Clinical News

Human heterologous liver cells regulatory update

...The COMP issued a positive opinion to grant Orphan Drug designation for Cytonet's human heterologous liver...
...1 and carbamoyl-phosphate synthetase-1 deficiency. The COMP is part of the European Medicines Agency (EMA). Cytonet GmbH & Co. KG...
BioCentury | Jul 30, 2007
Clinical News

Human heterologous liver cells regulatory update

...Orphan Drug designation for Cytonet's human heterologous liver cells for the treatment of ornithine-transcarbamylase deficiency. Cytonet GmbH & Co. KG...
BioCentury | Jan 22, 2007
Company News

Cytonet, Vesta Therapeutics Inc. deal

...Vesta will manufacture Cytonet's liver cell therapies for up to two years. Cytonet's HHLivC heterologous liver...
...in liver failure by year end, valued the supply agreement in the millions of dollars. Cytonet GmbH & Co. KG...
Items per page:
1 - 10 of 13
BioCentury | Jun 22, 2018
Finance

Regenerating eastward

...donors. Promethera has four hepatic programs -- two cell therapies developed in-house, another acquired from Cytonet GmbH & Co. KG...
...therapies. The mAb has anti-inflammatory effects in preclinical models. Promethera’s most advanced program, Heparesc from Cytonet...
...to change the company’s calculus. Although Promethera gained a facility in North Carolina through the Cytonet...
BioCentury | May 2, 2016
Company News

Cytonet, Promethera deal

...Promethera acquired Cytonet’s “key” assets, including Heparesc . Promethera also will receive a U.S. Cytonet facility...
...product manufacturing and liver sourcing with a U.S. organ procurement organization. A team of seven Cytonet...
...and that Cytonet’s lead shareholder will receive up to a 13% equity stake in Promethera. Cytonet GmbH & Co. KG...
BioCentury | Oct 26, 2015
Emerging Company Profile

Building bacteria

...data comparing Syn1010 with Ravicti. Gutiérrez-Ramos said cell therapies in the clinic require diet restrictions. Cytonet GmbH & Co. KG's...
...receiving HepaStem will be able to eat more proteins, but it still recommends low-protein diets. Cytonet...
...and Institutions Mentioned BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), San Rafael, Calif. Boston University , Boston, Mass. Cytonet GmbH & Co. KG...
BioCentury | May 25, 2015
Finance

Innovation underfed

...up front plus $140 million in milestones. Another innovator in registration from the cohort is Cytonet GmbH & Co. KG...
...treat pediatric urea cycle disorders (UCD). Promethera Biosciences S.A. is a couple of years behind Cytonet...
...Germany Cardiorentis AG, Zug, Switzerland Circassia Pharmaceuticals plc (LSE:CIR), Oxford, U.K. CureVac GmbH, Tuebingen, Germany Cytonet GmbH & Co. KG...
BioCentury | Feb 10, 2014
Clinical News

Liver cell therapy regulatory update

...U.S. and Canadian Phase II SELICA III trial in infants and children ages <=5 years. Cytonet GmbH & Co. KG...
BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...90% Novel drug class; deal with Sanofi- Pasteur, the vaccines division of Sanofi (Euronext:SAN; NYSE:SNY) Cytonet GmbH & Co. KG...
BioCentury | Apr 25, 2011
Clinical News

Human heterologous liver cells: Phase II started

...trial to evaluate infusions of human heterologous liver cells in 20 infant and pediatric patients. Cytonet GmbH & Co. KG...
BioCentury | Oct 25, 2010
Clinical News

Human heterologous liver cells regulatory update

...The COMP issued a positive opinion to grant Orphan Drug designation for Cytonet's human heterologous liver...
...1 and carbamoyl-phosphate synthetase-1 deficiency. The COMP is part of the European Medicines Agency (EMA). Cytonet GmbH & Co. KG...
BioCentury | Jul 30, 2007
Clinical News

Human heterologous liver cells regulatory update

...Orphan Drug designation for Cytonet's human heterologous liver cells for the treatment of ornithine-transcarbamylase deficiency. Cytonet GmbH & Co. KG...
BioCentury | Jan 22, 2007
Company News

Cytonet, Vesta Therapeutics Inc. deal

...Vesta will manufacture Cytonet's liver cell therapies for up to two years. Cytonet's HHLivC heterologous liver...
...in liver failure by year end, valued the supply agreement in the millions of dollars. Cytonet GmbH & Co. KG...
Items per page:
1 - 10 of 13